Loading...
Docoh

Tcr2 Therapeutics (TCRR)

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

TCRR stock data

Analyst ratings and price targets

Last 3 months

Calendar

8 Aug 22
11 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 45.36M 45.36M 45.36M 45.36M 45.36M 45.36M
Cash burn (monthly) 9.97M 17.05M 10.59M 9.57M 6.51M 7.78M
Cash used (since last report) 14.03M 23.98M 14.9M 13.46M 9.16M 10.94M
Cash remaining 31.34M 21.38M 30.47M 31.9M 36.2M 34.42M
Runway (months of cash) 3.1 1.3 2.9 3.3 5.6 4.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Jun 22 Eric Sullivan Stock Option Common Stock Grant Acquire A No No 2.89 250,000 722.5K 250,000
28 Feb 22 Justice Angela Common Stock Grant Acquire A No No 2.3 2,236 5.14K 9,693
28 Feb 22 Menzel Garry E Common Stock Grant Acquire A No No 2.3 1,425 3.28K 180,932
80.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 94 121 -22.3%
Opened positions 15 39 -61.5%
Closed positions 42 35 +20.0%
Increased positions 24 33 -27.3%
Reduced positions 35 35
13F shares Current Prev Q Change
Total value 121.91M 789.6M -84.6%
Total shares 31.2M 30.46M +2.4%
Total puts 22.5K 58.1K -61.3%
Total calls 0 30.7K EXIT
Total put/call ratio Infinity 1.9 +Infinity%
Largest owners Shares Value Change
MPM Asset Management 4.05M $11.18M 0.0%
MPM Oncology Impact Management 3.37M $9.3M 0.0%
Tang Capital Management 3M $8.28M NEW
Tang Capital Partners 2.8M $7.5M NEW
BLK Blackrock 2.53M $6.99M +5.5%
Renaissance Technologies 1.44M $3.98M +61.7%
Upnorth Investment 1.28M $39.63M 0.0%
Redmile 1.09M $3.02M -18.7%
Vanguard 1.03M $2.85M -23.7%
D. E. Shaw & Co. 802.51K $2.22M +80.8%
Largest transactions Shares Bought/sold Change
Tang Capital Management 3M +3M NEW
Tang Capital Partners 2.8M +2.8M NEW
Millennium Management 99.47K -1.35M -93.1%
BAC Bank Of America 215.93K -1.01M -82.4%
Wellington Management 0 -835.33K EXIT
Renaissance Technologies 1.44M +550.7K +61.7%
Acadian Asset Management 479.52K +465.21K +3250.7%
D. E. Shaw & Co. 802.51K +358.75K +80.8%
Point72 Asset Management 0 -350K EXIT
Parametric Portfolio Associates 43.12K -321.6K -88.2%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Good
New words: cyber, network, premium, subsidiary, unpaid
Removed: contracted, deleting, generation, payable, supplement

Patents

Utility
Compositions and methods for TCR reprogramming using fusion proteins
5 Jul 22
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Utility
Compositions and methods for TCR reprogramming using fusion proteins
8 Feb 22
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
25 Nov 21
Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
Utility
Compositions and Methods for TCR Reprogramming Using Target Specific Fusion Proteins
14 Oct 21
Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13Rα2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Utility
Compositions and Methods for TCR Reprogramming Using Fusion Proteins
19 Aug 21
Provided herein are T cell receptor (TCR) fusion proteins (TFPs) having specificity for more than one tumor cell associated antigen, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.